tetano
Editor, Senior Moderator
J Med Virol
. 2023 Jun;95(6):e28823.
doi: 10.1002/jmv.28823. Statins in hospitalized COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials
Yajuan Ren[SUP] 1 [/SUP], Guizuo Wang[SUP] 1 [/SUP], Dong Han[SUP] 1 [/SUP]
Affiliations
This systematic review and meta-analysis aimed to determine the efficacy of statins in hospitalized patients with coronavirus disease-2019 (COVID-19). A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of COVID-19 with statins, compared with placebo or standard of care, were reviewed. Seven RCTs (enrolling 1830 participants) met the inclusion criteria. There was no statistically significant difference in all-cause mortality (risk ratio [RR]: 0.92, 95% confidence interval [CI]: 0.75-1.13), length of hospital stay (weighted mean difference: -0.21 days, 95% CI: -1.01 to 0.59 days), intensive care unit (ICU) admission (RR: 1.84, 95% CI: 0.45-7.55), and mechanical ventilation (RR: 1.09, 95% CI: 0.70-1.70) between the two groups. Statins failed to reduce mortality, ICU admission, mechanical ventilation, and length of stay in hospitalized patients with COVID-19. Statins probably should not be used routinely in COVID-19 patients.
Keywords: SARS coronavirus; antiviral agents; coronavirus.
. 2023 Jun;95(6):e28823.
doi: 10.1002/jmv.28823. Statins in hospitalized COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials
Yajuan Ren[SUP] 1 [/SUP], Guizuo Wang[SUP] 1 [/SUP], Dong Han[SUP] 1 [/SUP]
Affiliations
- PMID: 37254831
- DOI: 10.1002/jmv.28823
This systematic review and meta-analysis aimed to determine the efficacy of statins in hospitalized patients with coronavirus disease-2019 (COVID-19). A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of COVID-19 with statins, compared with placebo or standard of care, were reviewed. Seven RCTs (enrolling 1830 participants) met the inclusion criteria. There was no statistically significant difference in all-cause mortality (risk ratio [RR]: 0.92, 95% confidence interval [CI]: 0.75-1.13), length of hospital stay (weighted mean difference: -0.21 days, 95% CI: -1.01 to 0.59 days), intensive care unit (ICU) admission (RR: 1.84, 95% CI: 0.45-7.55), and mechanical ventilation (RR: 1.09, 95% CI: 0.70-1.70) between the two groups. Statins failed to reduce mortality, ICU admission, mechanical ventilation, and length of stay in hospitalized patients with COVID-19. Statins probably should not be used routinely in COVID-19 patients.
Keywords: SARS coronavirus; antiviral agents; coronavirus.